<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114371</url>
  </required_header>
  <id_info>
    <org_study_id>15 7837 03</org_study_id>
    <secondary_id>2016-003273-18</secondary_id>
    <nct_id>NCT03114371</nct_id>
  </id_info>
  <brief_title>Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years</brief_title>
  <acronym>Oxyjeune</acronym>
  <official_title>Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positive results in preclinical and clinical studies in adults and infants with Prader-Willi
      syndrome lead investigators to set up a new study in children with Prader-Willi syndrome. The
      objective of this study is to document effects of oxytocin intranasal administrations on
      behavioural troubles in children with Prader-Willi syndrome aged from 3 to 12 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups of patients will be constituted according to their age; &quot;Group 1&quot; children aged
      from 3 to 6 years (n = 20) and &quot;Group 2&quot; children aged from 7 to 12 years (n = 20). Within
      each group, subjects will be randomized to receive either oxytocin or placebo for 12
      consecutive weeks. A second period of 12 consecutive oxytocin treatment weeks will then be
      performed for all patients, followed by a 4-week observation period to document effects after
      discontinuation of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Children will receive after randomization either placebo or oxytocin administration (daily intranasal) for a total duration of 12 consecutive weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The packaging, presentation and labelling of the bottles used during the blind phase will guarantee the blindness to the healthcare team and the patient.
The allocation of the treatment arms to each treatment number will be carried out according to the randomization table established beforehand.
Until the end of the study, neither the investigating physician nor the patient will know the group to which the patient has been randomly assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of behavioural troubles evaluated by the global score of Child Behavior Check List Questionnaire after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Week 12</time_frame>
    <description>It's variation between inclusion and 12 weeks of total score total problems from the Child Behavior Check List Questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hyperphagia after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is the variation of each of the three sub-scores obtained from the Dykens hyperphagia questionnaire between day 0 and week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of social skills after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is variation between day 0 and week 12 of the total score obtained from the social skills assessment questionnaire for children aged from 3 to 6 years and the Social Responsiveness Scale questionnaire for children aged from 7 to 12 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of auto- and hetero-aggressive after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is variation between day 0 and week 12 of the total score obtained from the self-aggression assessment questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of psychopathology after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is the variation of the following sub-scores obtained from the Child Behaviour Check List questionnaire (only the following 3 subscales) between day 0 and week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of global clinical status after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Weeks 12</time_frame>
    <description>It is improvement of the patient's overall clinical condition after 12 weeks of treatment with oxytocin/placebo. It's assessed by the Clinical Global Impression Scale's score.
This scale of improvement of Clinical Global Impression is a 7-point ordinal qualitative scale of &quot;very greatly improved&quot; rated + 3 to &quot;very strongly aggravated&quot; rated -3. The result is expressed in total score which varies from -3 to +3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acyl and desacyl ghrelin plasma levels after 12 weeks of oxytocin/placebo treatment.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is evolution of circulating levels of acylated and deacylated ghrelin will be the variations of these rates and the variation of the relationships between day 0 and week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of attentional abilities after 12 weeks of oxytocin/placebo treatment, for patients aged from 7 to 12 years at inclusion.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is evolution of attentional abilities is evaluated by a computerized test, the Attention Network Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of metabolic brain resting state after 12 weeks of oxytocin/placebo treatment, for patients aged from 7 to 12 years at inclusion.</measure>
    <time_frame>Week 12</time_frame>
    <description>It is evolution of metabolic brain resting state is evaluated by a magnetic resonance imaging to study the cerebral metabolism between day 0 and week 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Intranasal administration of oxytocin (Week 1 to 12)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Intranasal administration of placebo (Week 1 to 12)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Intranasal administration of oxytocin (Week 13 to 24)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a complete genetic diagnosis of Prader-Willi syndrome

          -  patient treated by growth hormone for at least 1 year

          -  patient naïve for oxytocin for at least 5 years

        Exclusion Criteria:

          -  patient who do not accept intranasal administrations (major behavioural trouble)

          -  patient with hepatic insufficiency : serum transaminases (SGOT, SGPT) higher than 3
             times normal values for age

          -  patient with renal insufficiency : serum creatinine higher than 3 times normal values
             for age

          -  patient with an antecedent of abnormal electrocardiogram

          -  patient with arterial hypertension or hypotension

          -  patient with type 1 or 2 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie ÇABAL-BERTHOUMIEU, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de référence du syndrome de Prader-Willi, Hôpital des Enfants</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie ÇABAL-BERTHOUMIEU, Dr</last_name>
    <phone>5 34 55 74 32</phone>
    <phone_ext>33</phone_ext>
    <email>cabal-berthoumieu.s@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de référence du syndrome de Prader-Willi Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ÇABAL-BERTHOUMIEU, Dr</last_name>
      <phone>5 34 55 74 32</phone>
      <phone_ext>33</phone_ext>
      <email>cabal-berthoumieu.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bittel DC, Kibiryeva N, Sell SM, Strong TV, Butler MG. Whole genome microarray analysis of gene expression in Prader-Willi syndrome. Am J Med Genet A. 2007 Mar 1;143A(5):430-42.</citation>
    <PMID>17236194</PMID>
  </reference>
  <reference>
    <citation>Constantino JN, Todd RD. Intergenerational transmission of subthreshold autistic traits in the general population. Biol Psychiatry. 2005 Mar 15;57(6):655-60.</citation>
    <PMID>15780853</PMID>
  </reference>
  <reference>
    <citation>Dykens EM, Lee E, Roof E. Prader-Willi syndrome and autism spectrum disorders: an evolving story. J Neurodev Disord. 2011 Sep;3(3):225-37. doi: 10.1007/s11689-011-9092-5. Epub 2011 Aug 20.</citation>
    <PMID>21858456</PMID>
  </reference>
  <reference>
    <citation>Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring). 2007 Jul;15(7):1816-26.</citation>
    <PMID>17636101</PMID>
  </reference>
  <reference>
    <citation>Dykens E, Schwenk K, Maxwell M, Myatt B. The Sentence Completion and Three Wishes tasks: windows into the inner lives of people with intellectual disabilities. J Intellect Disabil Res. 2007 Aug;51(Pt 8):588-97.</citation>
    <PMID>17598872</PMID>
  </reference>
  <reference>
    <citation>Einfeld SL, Smith E, McGregor IS, Steinbeck K, Taffe J, Rice LJ, Horstead SK, Rogers N, Hodge MA, Guastella AJ. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am J Med Genet A. 2014 Sep;164A(9):2232-9. doi: 10.1002/ajmg.a.36653. Epub 2014 Jun 30.</citation>
    <PMID>24980612</PMID>
  </reference>
  <reference>
    <citation>Fan J, McCandliss BD, Sommer T, Raz A, Posner MI. Testing the efficiency and independence of attentional networks. J Cogn Neurosci. 2002 Apr 1;14(3):340-7.</citation>
    <PMID>11970796</PMID>
  </reference>
  <reference>
    <citation>Goldstone AP, Holland AJ, Butler JV, Whittington JE. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes (Lond). 2012 Dec;36(12):1564-70. doi: 10.1038/ijo.2011.274. Epub 2012 Jan 24.</citation>
    <PMID>22270375</PMID>
  </reference>
  <reference>
    <citation>Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010 Apr 1;67(7):692-4. doi: 10.1016/j.biopsych.2009.09.020. Epub 2009 Nov 7.</citation>
    <PMID>19897177</PMID>
  </reference>
  <reference>
    <citation>Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015 Apr;56(4):444-52. doi: 10.1111/jcpp.12305. Epub 2014 Aug 2.</citation>
    <PMID>25087908</PMID>
  </reference>
  <reference>
    <citation>Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012 Apr;37(4):509-18. doi: 10.1016/j.psyneuen.2011.07.020. Epub 2011 Aug 20.</citation>
    <PMID>21862226</PMID>
  </reference>
  <reference>
    <citation>Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6.</citation>
    <PMID>15931222</PMID>
  </reference>
  <reference>
    <citation>Lischke A, Gamer M, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC, Domes G. Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology. 2012 Sep;37(9):1431-8. doi: 10.1016/j.psyneuen.2012.01.011. Epub 2012 Feb 23.</citation>
    <PMID>22365820</PMID>
  </reference>
  <reference>
    <citation>MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011 Sep;36(8):1114-26. doi: 10.1016/j.psyneuen.2011.02.015. Epub 2011 Mar 23. Review.</citation>
    <PMID>21429671</PMID>
  </reference>
  <reference>
    <citation>Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscoll DJ. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011 May;155A(5):1040-9. doi: 10.1002/ajmg.a.33951. Epub 2011 Apr 4.</citation>
    <PMID>21465655</PMID>
  </reference>
  <reference>
    <citation>Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F. A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Hum Mol Genet. 2010 Dec 15;19(24):4895-905. doi: 10.1093/hmg/ddq424. Epub 2010 Sep 28.</citation>
    <PMID>20876615</PMID>
  </reference>
  <reference>
    <citation>Skokauskas N, Sweeny E, Meehan J, Gallagher L. Mental health problems in children with prader-willi syndrome. J Can Acad Child Adolesc Psychiatry. 2012 Aug;21(3):194-203.</citation>
    <PMID>22876265</PMID>
  </reference>
  <reference>
    <citation>Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab. 1995 Feb;80(2):573-9.</citation>
    <PMID>7852523</PMID>
  </reference>
  <reference>
    <citation>Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, Rogé B, Laurier V, Ehlinger V, Arnaud C, Molinas C, Thuilleaux D. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011 Jun 24;6:47. doi: 10.1186/1750-1172-6-47.</citation>
    <PMID>21702900</PMID>
  </reference>
  <reference>
    <citation>van Lieshout CF, de Meyer RE, Curfs LM, Koot HM, Fryns JP. Problem behaviors and personality of children and adolescents with Prader-Willi syndrome. J Pediatr Psychol. 1998 Apr;23(2):111-20.</citation>
    <PMID>9585637</PMID>
  </reference>
  <reference>
    <citation>Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016 Sep;21(9):1225-31. doi: 10.1038/mp.2015.162. Epub 2015 Oct 27.</citation>
    <PMID>26503762</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prader-Willi syndrome</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Behavioural troubles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

